Assessing DCog Short for Neurotoxicity in CAR-T

Starting soon · Not applicable

Conditions studied: Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy, Immune Effector Cell Associated Neurotoxicity Syndrome

In brief

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.

Key facts

Study ID

NCT07403812

Run by

Beth Israel Deaconess Medical Center

People needed

40

Starts

2026-07-01

Expected to finish

2027-08-31

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.
• Visual acuity of 20/100 or better.

You may not qualify if…

• patients < 18 years old
• pregnant women
• prisoners
• adults unable to consent,
• participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.